Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-4357 in PSMA-positive mCRPC
NCT07311694Phase 3Recruiting
- Sponsor
- Hengrui
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HRS-4357 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Hengrui. Started Feb 2026; status: recruiting.
02
Drugs
HRS-4357
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07311694.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07311694.